Local support for stem cell research hides a massive ethical and economic battleground. Who truly profits from this 'good cause'?
The annual Rocky Mountain IP Institute convenes, but the real battle for **technology** dominance isn't in the lecture halls—it's in the shadows of **patent litigation**.
Forget the glossy press releases. The true impact of science and tech initiatives in Kano reveals a deeper geopolitical struggle over digital sovereignty.
Gilead's massive $7.8bn acquisition of Arcellx isn't just about pipeline depth; it’s a brutal market consolidation signal in the competitive **biotech M&A** landscape.
Syndex Bio's $15.5M seed funding and mcPCR reveal the truth about next-gen sequencing bottlenecks.
Viral mimic systems promise faster vaccine creation, but the real battle is over intellectual property and manufacturing control. This is the unspoken truth.
Cornell's Mehta Group pushes 'precision nutrition' tech. This isn't about health; it's about data control in the future of food security.
Beyond the headlines of hair regrowth and ancient DNA, this week in science reveals a dangerous trend: trivializing genuine biological trauma.
The 'Prompt-to-Drug' concept isn't just faster drug discovery; it's a seismic shift threatening the entire structure of pharmaceutical R&D.
The official visit of Japan's top science advisor signals a desperate pivot in global **technology transfer**—and the US might be the unwitting supplier.
Argentina tweaks the RIGI framework, but the unspoken truth is who really benefits from this supposed technology investment boom.
The KU/Children's Mercy theranostics center is more than a building; it's a strategic play to dominate advanced nuclear medicine, leaving competitors flat-footed.